avaleaf aims to become the preferred partner and leading platform for medical cannabis in Germany, and throughout Europe, by connecting producers, payers such as insurance companies or sick funds, healthcare professionals, and authorities to provide best possible medical cannabis solutions to patients in need. avaleaf aims to achieve this mission by:
In March 2017, the German government legalized medical cannabis, enabling full reimbursement by health insurance. Since then, the use of medical cannabis has increased significantly. In the eight years between November 2008 and March 2017, import licenses equivalent to a total of four metric tons have been granted. Since then the situation has changed dramatically. In 2017, the number of patients using medical cannabis increased from several hundred to 35,000. And an estimated 13 metric tons of medical cannabis was sold in Germany, a country of more than 82 million people. The market is expected to grow to 26 tons in 2018 and 40 tons in 2019. With the increased availability and use of oils, extracts, and cannabinoid-based pharmaceuticals it is anticipated that up to 400,000 patients (equivalent to 0.5% of the German population) will benefit from medical cannabis in various forms within the next five to eight years.
At present, with the demand being much higher than the supply, many patients are not able to receive medical cannabis in time, and often only it is low quality. Stock outs are a common experience even for terminally ill patients.
After the first tender was reappraised due to legal actions, German authorities tendered out a slightly increased amount of 10.4 metric tons of medical cannabis for local production between 2020 and 2023. However, this will not improve the supply situation significantly, and the German healthcare system will have to heavily rely on cannabis imports for years to come.
With the expected growth of the cannabis market, additional importers and distributors are needed, especially taking into account that not all recently founded enterprises will continue their business operations, due to lack of business experience, financing, and/or lack of supply.
PhD, MD, JD
Sven’s focus at avaleaf is on regulatory affairs and marketing & sales, including outreach to authorities, payers, healthcare providers, and patients.
Sven has over 25 years of experience in pharma and healthcare with deep knowledge and understanding of the German and various other European healthcare systems. In 2011, he founded SVEN SAUER HEALTHCARE CONSULTING, which successfully provides services to the pharmaceutical and medical devices industry in Germany and Europe. Prior to that he held several senior executive roles with Eli Lilly in Germany, the US and across Europe; and he worked for McKinsey, consulting payers and pharma companies nationally and internationally. He started his medical career in neurology/neuroradiology, and gained legal experience in malpractice/physicians’ law.
Sven holds degrees in law from Mainz university, and medicine from Frankfurt university, and is fully licensed in both professions.
Please contact avaleaf GmbH at